Latest database descriptions

General objective: To evaluate the medical, clinical, biological and therapeutic characteristics of breast cancer patients receiving neoadjuvant chemotherapy Secondary objectives: - To evaluate the long-term impact of therapeutic schemas on recurrence-free overall survival; - To validate the current prognostic scores from a U.S. population on an independent French cohort; - To identify prognostic variables and select those relevant to the establishment and evaluation of a new score from our database to reflect new biological data (Chevallier and Sataloff scores and molecular classification); - To compare the prognostic qualities of the new score to the U.S. score; - To conduct an external validation of these scores (through collaboration with the Institut Gustave Roussy team in Villejuif and the Institute Bergonie team in Bordeaux); - To isolate genetic (constitutional), genomic (tumour) or immunohistological factors with predictive power for treatment response and prognosis.

This survey's objectives are to:
- find out the main health condition indicators, medical practices
during pregnancy and delivery and perinatal risk factors; it will
thus be possible to monitor their trends from previous national surveys
(1995, 1998 and 2003);
- provide a national sample with which it is possible to compare
département or regional data from other sources;
- provide information for guiding public health decisions and evaluate
health actions in the perinatal field.

The main objective is to evaluate the rate of secondary metastases resection at 12 months in real-life conditions of use in patients with colorectal cancer treated by Cetuximab® first line metastatic.

- to identify predictive factors of response to bariatric surgery in order to improve treatment - to identify long-term complications of bariatric surgery.